• Revenues increased 8% to $95 million
• Profit before tax up 2% to $51.6 million
• Net profit up 2% to $36.2 million
• Fully franked final dividend of $0.05 per share declared

Clinuvel Pharmaceuticals Ltd has reported its financial results for the 2025 fiscal year, which ended on 30 June 2025. The company saw an 8% increase in revenues from ordinary activities to $95,017,570, while profit from ordinary activities before tax attributable to members increased by 2% to $51,552,800. Net profit for the period attributable to members also rose 2% to $36,172,518. The directors have declared a fully franked final dividend of $0.05 per ordinary share, to be paid on 19 September 2025. The company's audited Annual Report for the year ended 30 June 2025 accompanies this announcement, providing further details on the financial results and operational performance. Clinuvel continues to focus on the development and commercialization of its lead product, SCENESSE(R) (afamelanotide), for the treatment of erythropoietic protoporphyria (EPP) in the United States and the potential expansion into the treatment of vitiligo. The company has made significant progress in building its specialty center network across North America to distribute SCENESSE(R) and prepare for the potential launch of the vitiligo treatment.

Clinuvel remains focused on advancing its clinical programs, particularly the Phase III vitiligo study (CUV105) which completed recruitment in May 2025. The company is also working towards the final design of the CUV107 study as it looks to provide a compelling dossier to the FDA for an expansion of the SCENESSE(R) label to include the treatment of vitiligo.